Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. (ELOX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
elox · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Eloxx Pharmaceuticals, Inc. (ELOX) measures how much investors pay for each dollar of the company's trailing earnings. ELOX's current PE ratio of N/A is calculated by dividing its stock price of $6.20 by its TTM earnings per share of -$1.25.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Eloxx Pharmaceuticals, Inc.You ELOX | $47M | N/A | — | -$1.25 |
 Biocept, Inc. BIOCQ | $0M | N/A | — | -$56.78 |
 Cardax, Inc. CDXI | $0M | N/A | — | -$6.79 |
 HTG Molecular Diagnostics, Inc. HTGMQ | $0M | N/A | — | -$24.28 |
 MedAvail Holdings, Inc. MDVLQ | $0M | N/A | — | -$36.20 |
 Micron Solutions, Inc. MICRD | $0M | N/A | — | -$0.41 |
 Nabriva Therapeutics plc NBRVF | $0M | N/A | — | -$21.32 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.34 | — | |
2024-12-31 FY2024 | — | $0.00 | — | |
2023-12-31 FY2023 | — | $0.00 | — | |
2022-12-31 FY2022 | — | $-183.15 | — | |
2021-12-31 FY2021 | — | $-419.69 | — | |
2020-12-31 FY2020 | — | $-379.20 | — | |
2019-12-31 FY2019 | — | $-588.15 | — | |
2018-12-31 FY2018 | — | $-640.13 | — | |
2017-12-31 FY2017 | — | $-1875.89 | — | |
2016-06-30 FY2016 | — | $-3580.53 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Eloxx Pharmaceuticals, Inc. (ELOX) measures how much investors pay for each dollar of the company's trailing earnings. ELOX's current PE ratio of N/A is calculated by dividing its stock price of $6.20 by its TTM earnings per share of -$1.25.
Frequently asked questions
ELOX pe ratio · 6 questionsELOX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.20 and TTM EPS of -$1.25. Data sourced from Financial Modeling Prep via ELOX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Eloxx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09